Trial Profile
AflacST1502: A Phase II Study of Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Feb 2024
Price :
$35
*
At a glance
- Drugs Celecoxib (Primary) ; Cyclophosphamide (Primary) ; Etoposide (Primary) ; Sirolimus (Primary)
- Indications Carcinoma; Choroid neoplasms; CNS cancer; Diffuse intrinsic pontine glioma; Glioma; Histiocytosis; Medulloblastoma; Neuroepithelial neoplasms; Rhabdoid tumour; Solid tumours; Teratoma
- Focus Therapeutic Use
- Acronyms AflacST1502
- 21 Feb 2024 Planned End Date changed from 1 Jan 2024 to 1 Feb 2025.
- 21 Feb 2024 Planned primary completion date changed from 1 Jan 2024 to 1 Feb 2025.
- 06 Jun 2023 Results of the CNS tumor stratum (n=22) assessing the efficacy of sirolimus in combination with metronomic chemotherapy, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.